Pathology

Immunogenetics (UIC)

Immunogenetic Samples
Immunogenetic Samples in Machine

About Us

The UCLA Immunogenetics Center (UIC) provides state-of-the-art Histocompatibility and Immunogenetics testing for solid organ and stem cell transplantation, pre- and post-transplant immune assessment and testing for diagnosis of diseases with associations to the Human Leukocyte Antigens (HLA). As one of the first established laboratories in Histocompatibility and Immunogenetics, we continue to advance the field through research, clinical innovation, proficiency testing and educational training. UIC provides customized testing and support services for clinical trials and clinical research to monitor response to experimental therapy.

The UIC is a nationally recognized reference laboratory for Histocompatibility and Immunogenetics testing and is licensed by the States of California, New York, Maryland, Pennsylvania and Rhode Island, and is CMS certified and accredited by the American Society for Histocompatibility and Immunogenetics (ASHI).

Goals and Mission

  • Leading Through Quality: Provide the highest standard of Immunogenetics, Histocompatibility and Transplantation Immunology testing and interpretation to the patients we serve.
  • Leading Through Research: Advance the understanding of Immunogenetics and Transplantation Immunology through innovative basic and clinical research.
  • Leading Through Development: Be the forefront of development of new technologies and reference materials to improve the quality of patient care.
  • Leading Through Training: Training the next generation of leaders in Histocompatibility and Immunogenetics to navigate the complexities of testing and research in Transplantation Immunology.

Recent Publications

  • Bergersen KV, Zheng Y, Rossetti M, Ruffin F, Pickering H, Parmar R, Sunga G, Chan LC, Gjertson D, Fowler VG, Yeaman MR, Reed EF; MRSA Systems Immunobiology Group. Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia. BMC Infect Dis. 2025 Feb
  • Philogene MC, Timofeeva OA, Gimferrer I, Hod-Dvorai R. Assessment of Inter-Laboratory Variability for Flow Cytometric Crossmatch Testing: Lessons Learned from Proficiency Surveys. Hum Immunol. 2025 Jan
  • Al-Hussaini A, Alsaheel A, AlMalki M, Troncone R, Alharthi H, Eltayeb-Elsheikh N, Alshammari G, Allah SZ, Aldossari G, AlRajhi N, Abdulkareem F, Alzahrani A, AlNemer O, AlMazrou L, Bashir MS. Is HLA-DQ typing useful in screening for celiac disease among Arabs with type 1 diabetes? A case-control study. J Pediatr Gastroenterol Nutr. 2024 Dec
  • Fedrigo M, Berry GJ, Coutance G, Reed EF, Lin CY, Giarraputo A, Kransdorf E, Thaunat O, Goddard M, Angelini A, Neil DAH, Bruneval P, Duong Van Huyen JP, Loupy A, Miller DV. Report of the 2022 Banff Heart Concurrent: Focus on non-human leukocyte antigen antibodies in rejection and the pathology of "mixed" rejection. Am J Transplant. 2024 Apr
  • Zhang Q, Locke AF, Alvarez AC, Cabarong ML, Liv LC, Alfaro BGP, Gjertson DW, Reed EF. Advancing precision in histocompatibility and immunogenetics: a comprehensive review of the UCLA exchange program. Front Genet. 2024 Feb
  • Yin Y, Soe NN, Valenzuela NM, Reed EF, Zhang Q. HLA-DPB1 genotype variants predict DP molecule cell surface expression and DP donor specific antibody binding capacity. Front Immunol. 2024 Jan
  • Sosa RA, Ahn R, Li F, Terry AQ, Qian Z, Bhat A, Sen S, Naini BV, Ito T, Kaldas FM, Hoffmann A, Busuttil RW, Kupiec-Weglinski JW, Gjertson DW, Reed EF. Myeloid spatial and transcriptional molecular signature of ischemia-reperfusion injury in human liver transplantation. Hepatol Commun. 2024 Jan